Skip to main content
SpringerLink
Log in
Book cover

Lymphoma and Leukemia of the Nervous System pp 357–381Cite as

Neurological Complications of Chemotherapy in Lymphoma and Leukemia Patients

  • Chapter
  • First Online:

  • 1006 Accesses

Abstract

The treatment of hematologic malignancies has markedly improved in recent decades. Patients are living longer, thus increasing the likelihood of long-term neurologic complications from chemotherapy. These neurologic sequelae are an important source of morbidity and may play a role in limiting potential therapies. The balance between efficacy and toxicity has become a major focus in recent clinical trials. This chapter reviews the most common neurologic complications of chemotherapy in leukemia and lymphoma patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Onciu M (2009) Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23:655–674

    PubMed  Google Scholar 

  2. Shipley JL, Butera JN (2009) Acute myelogenous leukemia. Exp Hematol 37:649–658

    PubMed  CAS  Google Scholar 

  3. Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8:581–592

    PubMed  CAS  Google Scholar 

  4. Hsi ED (2009) The leukemias of mature lymphocytes. Hematol Oncol Clin North Am 23:843–871

    PubMed  Google Scholar 

  5. Milojkovic D, Apperley J (2008) State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol 20:112–121

    PubMed  CAS  Google Scholar 

  6. Evens AM, Hutchings M, Diehl V (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 5:543–556

    PubMed  CAS  Google Scholar 

  7. Sweetenham JW (2008) Highly aggressive lymphomas in adults. Hematol Oncol Clin North Am 22:965–978, ix

    PubMed  Google Scholar 

  8. Thomas X, Le QH (2008) Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology 13:293–302

    PubMed  Google Scholar 

  9. Liesveld JL, Lichtman MA (2006) Acute myelogenous leukemia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds) Williams hematology, 7th edn. McGraw-Hill Medical, New York, NY, pp 1183–1236

    Google Scholar 

  10. Pfeifer H, Wassmann BJ, Hofmann WK (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 9:4674–4681

    PubMed  CAS  Google Scholar 

  11. Rytting ME, Wierda WG (2004) Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 45:1623–1626

    PubMed  Google Scholar 

  12. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815

    PubMed  CAS  Google Scholar 

  13. Denier C, Tertian G, Ribrag V et al (2009) Multifocal deficits due to leukemic meningoradiculitis in chronic lymphocytic leukemia. J Neurol Sci 277:130–132

    PubMed  CAS  Google Scholar 

  14. Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288

    PubMed  CAS  Google Scholar 

  15. Batchelor T, Carson K, O’Neil A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21(6):1044–1049

    PubMed  CAS  Google Scholar 

  16. Ferreri AJ, Crochhiolo R, Assanelli A et al (2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 49:2042–2047

    PubMed  CAS  Google Scholar 

  17. McAllister LD, Doolittle ND, Guastadisegni PE et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–60; discussion 60–1

    PubMed  CAS  Google Scholar 

  18. Shah GD, Yahalom J, Correa DD et al (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730–4735

    PubMed  CAS  Google Scholar 

  19. Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561–1567

    PubMed  CAS  Google Scholar 

  20. Tetef ML, Margolin KA, Doroshow JH et al (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19–26

    PubMed  CAS  Google Scholar 

  21. Vassal G, Valteau D, Bonnay M et al (1990) Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non-Hodgkin’s lymphoma. Pediatr Hematol Oncol 7:71–77

    PubMed  CAS  Google Scholar 

  22. Omuro AM, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595–1600

    PubMed  Google Scholar 

  23. Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16(3):859–863

    PubMed  CAS  Google Scholar 

  24. Abrey LE, Yahalom J, DeAngelis LM et al (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17):3144–3150

    PubMed  CAS  Google Scholar 

  25. Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574

    PubMed  CAS  Google Scholar 

  26. Seam P, Janik JE, DeAngelis LM et al (2009) Role of chemotherapy in Hodgkin’s lymphoma. Cancer J 15:150–154

    PubMed  Google Scholar 

  27. Brice P (2008) Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 141:3–13

    PubMed  Google Scholar 

  28. Quddus F, Armitage JO (2009) Salvage therapy for Hodgkin’s lymphoma. Cancer J 15:161–163

    PubMed  Google Scholar 

  29. Gribben JG (2007) How I treat indolent lymphoma. Blood 109:4617–4626

    PubMed  CAS  Google Scholar 

  30. Feuerlein K, Zucca E, Ghielmini M et al (2009) First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma 50:325–334

    PubMed  CAS  Google Scholar 

  31. Michallet AS, Coiffier B (2009) Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 23:11–23

    PubMed  CAS  Google Scholar 

  32. Friedberg JW, Fisher RI (2008) Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 22:941–952, ix

    Google Scholar 

  33. Wrench D, Gribben JG (2008) Stem cell transplantation for non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am 22:1051–1079, xi

    PubMed  Google Scholar 

  34. Lim HY, Thiel E, Glantz MJ (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin’s lymphoma. Curr Opin Oncol 20:495–501

    PubMed  Google Scholar 

  35. Mead GM, Sydes MR, Walewski J et al (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom lymphoma group LY06 study. Ann Oncol 13:1264–1274

    PubMed  CAS  Google Scholar 

  36. Magrath I, Adde M, Shad A et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934

    PubMed  CAS  Google Scholar 

  37. Lippens RJ, Winograd B (1988) Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 5:115–124

    PubMed  CAS  Google Scholar 

  38. Geiser CF, Bishop Y, Jaffe N et al (1975) Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 45:189–195

    PubMed  CAS  Google Scholar 

  39. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402

    PubMed  CAS  Google Scholar 

  40. Phillips PC (1991) Methotrexate toxicity. In: Rottenberg DA (ed) Neurological complications of cancer treatment. Butterworth-heinemann, Boston, MA, pp 115–134

    Google Scholar 

  41. DeAngelis LM, Posner JB (2009) Side effects of chemotherapy: Neurologic complications of cancer. Oxford University Press, New York, NY, pp 447–510

    Google Scholar 

  42. Boogerd W, vd Sande JJ, Moffie D et al (1988) Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51(10):1277–1283

    PubMed  CAS  Google Scholar 

  43. Bates S, McKeever P, Masur H et al (1985) Myelopathy following intrathecal chemotherapy in a patient with extensive Burkitt’s lymphoma and altered immune status. Am J Med 78:697–702

    PubMed  CAS  Google Scholar 

  44. McLean DR, Clink HM, Ernst P et al (1994) Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes. Cancer 73:3037–3040

    PubMed  CAS  Google Scholar 

  45. Gagliano RG, Costanzi JJ (1976) Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 37:1663–1668

    PubMed  CAS  Google Scholar 

  46. Clark AW, Cohen SR, Nissenblatt MJ et al (1982) Paraplegia following intrathecal chemotherapy: neuropathologic findings and elevation of myelin basic protein. Cancer 50:42–47

    PubMed  CAS  Google Scholar 

  47. Counsel P, Khangure M (2007) Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol 62:172–176

    PubMed  CAS  Google Scholar 

  48. Lemann W, Wiley RG, Posner JB (1988) Leukoencephalopathy complicating intraventricular catheters: clinical, radiographic and pathologic study of 10 cases. J Neurooncol 6:67–74

    PubMed  CAS  Google Scholar 

  49. Baehring JM, Fulbright RK (2008) Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 79:535–539

    PubMed  CAS  Google Scholar 

  50. Riva D, Giorgi C, Nichellli F et al (2002) Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 59:48–53

    PubMed  CAS  Google Scholar 

  51. Dicuonzo F, Salvati A, Palma M et al (2009) Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol 24:1013–1018

    PubMed  Google Scholar 

  52. Winick NJ, Bowman WP, Kamen BA et al (1992) Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 84:252–256

    PubMed  CAS  Google Scholar 

  53. Yim YS, Mahoney DH Jr, Oshman DG (1991) Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 67:2058–2061

    PubMed  CAS  Google Scholar 

  54. Anderson SC, Baquies GD, Jackson A et al (2002) Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. Muscle Nerve 25(1):106–110

    PubMed  Google Scholar 

  55. Koh S, Nelson MD Jr, Kovanlikaya A et al (1999) Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 21:576–578

    PubMed  CAS  Google Scholar 

  56. Pascual AM, Coret F, Casanova B et al (2008) Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci 267(1-2):158–161

    PubMed  CAS  Google Scholar 

  57. Bernstein ML, Sobel DB, Wimmer RS (1982) Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid. Cancer 50:866–868

    PubMed  CAS  Google Scholar 

  58. Shore T, Barnett MJ, Phillips GL (1990) Sudden neurologic death after intrathecal methotrexate. Med Pediatr Oncol 18:159–161

    PubMed  CAS  Google Scholar 

  59. Paleologos N (1998) Complications of chemotherapy. In: Biller J (ed) Iatrogenic neurology. Butterworth-heinemann, Boston, MA, pp 439–460

    Google Scholar 

  60. Dietrich J, Wen PY (2008) Neurologic complications of chemotherapy. In: Schiff D, Kesari S, Wen PY (eds) Cancer neurology in clinical practice, Humana Press, Totowa, NJ, pp 287–326

    Google Scholar 

  61. Ettinger LJ (1982) Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 50:444–450

    PubMed  CAS  Google Scholar 

  62. Finkelstein Y, Zevin S, Heyol J et al (2004) Emergency treatment of life-threatening intrathecal methotrexate overdose. Neurotoxicology 25:407–410

    PubMed  Google Scholar 

  63. Spiegel RJ, Cooper PR, Blun RH et al (1984) Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 311:386–388

    PubMed  CAS  Google Scholar 

  64. Widemann BC, Balis FM, Shalabi A et al (2004) Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 96(20):1557–1559

    PubMed  CAS  Google Scholar 

  65. Wernick R, Smith DL (1989) Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 32:770–775

    PubMed  CAS  Google Scholar 

  66. Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146:489–503

    PubMed  CAS  Google Scholar 

  67. Rubnitz JE, Relling MV, Harrison PL et al (1998) Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 12:1176–1181

    PubMed  CAS  Google Scholar 

  68. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R et al (2001) Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 24:145–148

    PubMed  CAS  Google Scholar 

  69. Erbetta A, Salmaggi A, Sghirlanzoni A et al (2008) Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. Neurol Sci 29:131–137

    PubMed  Google Scholar 

  70. Martino RL, Benson AB, 3rd, Merritt JA et al (1984) Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 54:2003–2005

    PubMed  CAS  Google Scholar 

  71. Walker RW, Allen JC, Rosen G et al (1986) Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4:1845–1850

    PubMed  CAS  Google Scholar 

  72. Inaba H, Khan RB, Laninghan FH et al (2008) Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 19:178–184

    PubMed  CAS  Google Scholar 

  73. Borgna-Pignatti C, Battisti L, Marradi P et al (1992) Transient neurologic disturbances in a child treated with moderate-dose methotrexate. Br J Haematol 81:448

    PubMed  CAS  Google Scholar 

  74. Phillips PC, Dhawan Y, Strother SC et al (1987) Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 21:59–63

    PubMed  CAS  Google Scholar 

  75. Millot F, Dhondt JL, Hayte JM et al (1992) Impairment of cerebral biogenic amine synthesis in a patient receiving high-dose methotrexate. Am J Pediatr Hematol Oncol 14:276–278

    PubMed  CAS  Google Scholar 

  76. Chabner BA, Allegra CJ, Curt GA et al (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907–912

    PubMed  CAS  Google Scholar 

  77. Pizzo PA, Poplack DG, Blyer WA et al (1979) Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1:127–140

    PubMed  CAS  Google Scholar 

  78. Rubinstein LJ, Herman MM, Long TF et al (1975) Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 35:291–305

    PubMed  CAS  Google Scholar 

  79. Shuper A, Stark B, Kornreich L et al (2000) Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 15:573–580

    PubMed  CAS  Google Scholar 

  80. Lai R, Abrey LE, Rosenblum MK et al (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62:451–456

    PubMed  Google Scholar 

  81. Ochs J, Mulhern R, Fairclough D et al (1991) Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 9:145–151

    PubMed  CAS  Google Scholar 

  82. Oka M, Terae S, Kobayashi R et al (2003) MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45:493–497

    PubMed  CAS  Google Scholar 

  83. Price RA, Birdwell DA (1978) The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 42:717–728

    PubMed  CAS  Google Scholar 

  84. Davidson A, Payne G, Leach MO et al (2000) Proton magnetic resonance spectroscopy ((1)H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer. Med Pediatr Oncol 35:28–34

    PubMed  CAS  Google Scholar 

  85. Casey EB, Jellife AM, Le Quesne PM et al (1973) Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96:69–86

    PubMed  CAS  Google Scholar 

  86. Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1:421–427

    PubMed  CAS  Google Scholar 

  87. McLeod JG, Penny R (1969) Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 32:297–304

    PubMed  CAS  Google Scholar 

  88. Weintraub M, Adde MA, Venzon DJ et al (1996) Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 14:935–940

    PubMed  CAS  Google Scholar 

  89. Sandler SG, Tobin W, Henderson ES et al (1969) Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 19:367–374

    PubMed  CAS  Google Scholar 

  90. Nishikawa T, Kawakami K, Kumamoto T et al (2008) Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30:519–521

    PubMed  Google Scholar 

  91. Naumann R, Moham J, Reuner U et al (2001) Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol 115:323–325

    PubMed  CAS  Google Scholar 

  92. Munier F, Perentes E, Herbort CP et al (1992) Selective loss of optic nerve beta-tubulin in vincristine-induced blindness. Am J Med 93:232–234

    PubMed  CAS  Google Scholar 

  93. Gaidys WG, Dickerman JD, Walters CL et al (1983) Intrathecal vincristine. Report of a fatal case despite CNS washout. Cancer 52:799–801

    PubMed  CAS  Google Scholar 

  94. Robertson GL, Bhoopalam N, Zelkowitz LJ (1973) Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 132:717–720

    PubMed  CAS  Google Scholar 

  95. Hurwitz RL, Mahoney DH Jr, Armstrong DL et al (1988) Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 16:216–219

    PubMed  CAS  Google Scholar 

  96. Byrd RL, Rohrbaugh TM, Raney RB Jr et al (1981) Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 47:37–40

    PubMed  CAS  Google Scholar 

  97. Boranic M, Raci F (1979) A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 31:124–125

    PubMed  CAS  Google Scholar 

  98. Fazeny B, Zifko U, Meryn S et al (1996) Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study. Cancer Chemother Pharmacol 39:150–156

    PubMed  CAS  Google Scholar 

  99. Herzig RH, Hines JD, Herzig GP et al (1987) Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 5(6):927–932

    PubMed  CAS  Google Scholar 

  100. Hwang TL, Yung WK, Estey EH et al (1985) Central nervous system toxicity with high-dose Ara-C. Neurology 35:1475–1479

    PubMed  CAS  Google Scholar 

  101. Winkelman MD, Hines JD (1983) Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 14:520–527

    PubMed  CAS  Google Scholar 

  102. Gottlieb D, Bradstock K, Koutts J et al (1987) The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 60:1439–1441

    PubMed  CAS  Google Scholar 

  103. Smith GA, Damon LE, Rugo HS et al (1997) High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833–839

    PubMed  CAS  Google Scholar 

  104. Johnson NT, Crawford SW, Sargur M (1987) Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation. Bone Marrow Transplant 2:203–207

    PubMed  CAS  Google Scholar 

  105. Ritch PS, Hansen RM, Heuer DK (1983) Ocular toxicity from high-dose cytosine arabinoside. Cancer 51:430–432

    PubMed  CAS  Google Scholar 

  106. Baker WJ, Royer GL Jr, Weirs RB (1991) Cytarabine and neurologic toxicity. J Clin Oncol 9:679–693

    PubMed  CAS  Google Scholar 

  107. Luque FA, Selhorst JB, Petruska P (1987) Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 2:219–222

    PubMed  CAS  Google Scholar 

  108. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116

    PubMed  CAS  Google Scholar 

  109. Dunton SF, Nitschke R, Spruce WE et al (1986) Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A pediatric oncology group study. Cancer 57:1083–1088

    PubMed  CAS  Google Scholar 

  110. Resar LM, Phillips PC, Kastan MB et al (1993) Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 71:117–123

    PubMed  CAS  Google Scholar 

  111. Eden OB, Goldie W, Wood T et al (1978) Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia. Cancer 42:53–58

    PubMed  CAS  Google Scholar 

  112. Fort JA, Smith LD (1999) Pseudotumor cerebri secondary to intermediate-dose cytarabine HCl. Ann Pharmacother 33:576–578

    PubMed  CAS  Google Scholar 

  113. Kleinschmidt-DeMasters BK, Yeh M (1992) “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 70:2504–2507

    PubMed  CAS  Google Scholar 

  114. Watkin SW, Husband DJ, Green JA et al (1989) Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 25:1303–1310

    PubMed  CAS  Google Scholar 

  115. Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556–566

    PubMed  CAS  Google Scholar 

  116. Buesa JM, Garcia-Teijido P, Losa R et al (2003) Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 9:4636–4637

    PubMed  CAS  Google Scholar 

  117. Pelgrims J, De Vos F, Van den Brande J et al (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82:291–294

    PubMed  CAS  Google Scholar 

  118. Gieron MA et al (1988) Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neurooncol 6(1):29–30

    PubMed  CAS  Google Scholar 

  119. Shuper A, Stein J, Goshen J et al (2000) Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol 15:481–483

    PubMed  CAS  Google Scholar 

  120. Schachter S, Freeman R (1982) Transient ischemic attack and adriamycin cardiomyopathy. Neurology 32:1380–1381

    PubMed  CAS  Google Scholar 

  121. Arico M, Nespoli L, Porta F et al (1990) Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol 18:261–263

    PubMed  CAS  Google Scholar 

  122. Vandenberg SA, Kulig K, Spoerke DG et al (1988) Chlorambucil overdose: accidental ingestion of an antineoplastic drug. J Emerg Med 6:495–498

    PubMed  CAS  Google Scholar 

  123. Wyllie AR, Bayliff CD, Kovacs MJ (1997) Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 31:171–174

    PubMed  CAS  Google Scholar 

  124. Salloum E, Khan KK, Cooper DL (1997) Chlorambucil-induced seizures. Cancer 79:1009–1013

    PubMed  CAS  Google Scholar 

  125. Burns LJ (1992) Ocular toxicities of chemotherapy. Semin Oncol 19:492–500

    PubMed  CAS  Google Scholar 

  126. Chabner BA, Longo DL (1996) Cancer chemotherapy and biotherapy: principles and practice, Lippincott-Raven, Philadelphia, PA

    Google Scholar 

  127. Kende G, Sirkin SR, Thomas PR et al (1979) Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer 44:69–71

    PubMed  CAS  Google Scholar 

  128. Tashima CK (1975) Immediate cerebral symptoms during rapid intravenous administration of cyclophosphamide (NSC-26271). Cancer Chemother Rep 59:441–442

    PubMed  CAS  Google Scholar 

  129. Leff RS, Thompson JM, Daly MB et al (1988) Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 62:32–35

    PubMed  CAS  Google Scholar 

  130. Chamberlain MC, Tsao-wei DD, Groshen S (2006) Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106:2021–2027

    PubMed  CAS  Google Scholar 

  131. Cheson BD, Vena DA, Foss FM et al (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12:2216–2228

    PubMed  CAS  Google Scholar 

  132. Cohen RB, Abdsallah JM, Gray JR et al (1993) Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 118:114–116

    PubMed  CAS  Google Scholar 

  133. Spriggs DR, Stopa E, Mayer RJ et al (1986) Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 46:5953–5958

    PubMed  CAS  Google Scholar 

  134. Hammack JE, Cascino TL (1998) Chemotherapy and other common drug-induced toxicities of the central nervous system in patients with cancer. In: Vecht CJ (ed) Handbook of clinical neurology. Elsevier Science, Amsterdam, pp 481–514

    Google Scholar 

  135. Chun HG, Leyland-Jones BR, Caryk SM et al (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225–1228

    PubMed  CAS  Google Scholar 

  136. Warrell RP Jr, Berman E (1986) Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74–79

    PubMed  Google Scholar 

  137. Cid J, Revilla M, Cervera A et al (2000) Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 79:392–395

    PubMed  CAS  Google Scholar 

  138. Kiewe P, Seyfert S, Korper S et al (2003) Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 44:1815–1818

    PubMed  Google Scholar 

  139. Rodriguez L, Ribera JM, Batlle M et al (2002) Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine. Haematologica 87:ECR26

    PubMed  Google Scholar 

  140. Saumoy M, Castells G, Escoda L et al (2002) Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 43:433–436

    PubMed  Google Scholar 

  141. Sullivan KM, Storb R, Shulman HM et al (1982) Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 97:182–189

    PubMed  CAS  Google Scholar 

  142. Burger PC, Kamenar E, Schold SC et al (1981) Encephalomyelopathy following high-dose BCNU therapy. Cancer 48:1318–1327

    Google Scholar 

  143. Weiss HD, Walker MD, Wiernik PH (1974) Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med 291:127–133

    PubMed  CAS  Google Scholar 

  144. Postma TJ, van Groenigen CJ, Witjes RJ et al (1998) Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38(1):69–75

    PubMed  CAS  Google Scholar 

  145. Spivack SD (1974) Drugs 5 years later: procarbazine. Ann Intern Med 81:795–800

    PubMed  CAS  Google Scholar 

  146. Gutin PH, Levi JA, Wiernik PH et al (1977) Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 61:885–887

    PubMed  CAS  Google Scholar 

  147. Drappatz J, Schiff D, Kesaru S et al (2007) Medical management of brain tumor patients. Neurol Clin 25:1035–1071

    PubMed  Google Scholar 

  148. DeAngelis LM, Posner JB (2009b) Supportive care and its complications: Neurologic complications of cancer. Oxford University Press, New York, NY, pp 95–140

    Google Scholar 

  149. Batchelor TT, Taylor LP, Thaler HT et al (1997) Steroid myopathy in cancer patients. Neurology 48:1234–1238

    PubMed  CAS  Google Scholar 

  150. Dropcho EJ, Soong SJ (1991) Steroid-induced weakness in patients with primary brain tumors. Neurology 41:1235–1239

    PubMed  CAS  Google Scholar 

  151. Stiefel FC, Breitbart WS, Holland JC (1989) Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 7:479–491

    PubMed  CAS  Google Scholar 

  152. Lewis DA, Smith RE (1983) Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 5:319–332

    PubMed  CAS  Google Scholar 

  153. Baethge BA, Lidsky MD (1986) Intractable hiccups associated with high-dose intravenous methylprednisolone therapy. Ann Intern Med 104:58–59

    PubMed  CAS  Google Scholar 

  154. Haddad SF, Hitchon PW, Godersky JC (1991) Idiopathic and glucocorticoid-induced spinal epidural lipomatosis. J Neurosurg 74:38–42

    PubMed  CAS  Google Scholar 

  155. Caraceni A, Gangeri L, Martini C et al (1998) Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 83:482–489

    PubMed  CAS  Google Scholar 

  156. Meyers CA, Obbens EA, Scheibel RS et al (1991) Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68:88–92

    PubMed  CAS  Google Scholar 

  157. Meyers CA, Scheibel RS, Forman AD (1991) Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41:672–676

    PubMed  CAS  Google Scholar 

  158. Rohatiner AZ, Prior PF, Burton AC et al (1983) Central nervous system toxicity of interferon. Br J Cancer 47:419–422

    PubMed  CAS  Google Scholar 

  159. Spiegel RJ (1987) The alpha interferons: clinical overview. Semin Oncol 14:1–12

    PubMed  CAS  Google Scholar 

  160. Hensley ML, Peterson B, Silver RT et al (2000) Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 18:1301–1308

    PubMed  CAS  Google Scholar 

  161. Smedley H, Katrak M, Sikora K et al (1983) Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 286:262–264

    CAS  Google Scholar 

  162. Suter CC, Westmoreland BF, Shabrough FW et al (1984) Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 59:847–850

    PubMed  CAS  Google Scholar 

  163. Hejny C, Sternberg P, Lawson DH et al (2001) Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 131:782–787

    PubMed  CAS  Google Scholar 

  164. Vesikari T, Nuutila A, Cantell K (1988) Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 77:619–622

    PubMed  CAS  Google Scholar 

  165. Raison CL, Demetrashvili M, Capuron L et al (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19:105–123

    PubMed  CAS  Google Scholar 

  166. Michallet M, Maloisel F, Delain M et al (2004) Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 18:309–315

    PubMed  CAS  Google Scholar 

  167. Adamson PC, Reaman G, Finklestein JZ et al (1997) Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol 15:3330–3337

    PubMed  CAS  Google Scholar 

  168. Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021–1028

    PubMed  CAS  Google Scholar 

  169. Maloney DG, Press OW (1998) Newer treatments for non-Hodgkin’s lymphoma: monoclonal antibodies. Oncology (Williston Park) 12:63–76

    CAS  Google Scholar 

  170. Foran JM, Rohatiner AZ, Cunninghan D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317–324

    PubMed  CAS  Google Scholar 

  171. Kaminski MS, Estes J, Zasadny KR et al (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259–1266

    PubMed  CAS  Google Scholar 

  172. Vose JM, Wahl RL, Saleh M et al (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 18:1316–1323

    PubMed  CAS  Google Scholar 

  173. Dillman RO, Hendrix CS (2003) Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 1:38–48

    PubMed  Google Scholar 

  174. Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164

    PubMed  CAS  Google Scholar 

  175. Apisarnthanarax N (2002) Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 3:193–215

    PubMed  Google Scholar 

  176. Olsen E, Duvic M, Frankal A et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376–388

    PubMed  CAS  Google Scholar 

  177. Deininger MW, O’Brien SG, Ford JM et al (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21:1637–1647

    PubMed  CAS  Google Scholar 

  178. Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

    PubMed  CAS  Google Scholar 

  179. Penel N, Blay JY, Adenis A et al (2008) Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 358:2746–2747

    PubMed  CAS  Google Scholar 

  180. Song KW, Rifkind J, Al-Beirouti B et al (2004) Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 45:1633–1636

    PubMed  CAS  Google Scholar 

  181. Schiff D, Wen PY, van den Bent MJ et al (2009) Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 6:596–603

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuro-Oncology, Department of Neurology, Dana Farber Cancer Institute, Center for Neuro-Oncology, Brigham and Women’s Hospital, Boston, MA, 02115, USA

    Eudocia C. Quant & Patrick Y. Wen

  2. Division of Hematologic Malignancies, Department of Medicine, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA, 02115, USA

    David C. Fisher

Authors
  1. Eudocia C. Quant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David C. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Y. Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Y. Wen .

Editor information

Editors and Affiliations

  1. , Stephen E. and Catherine Pappas Center f, Massachusetts General Hospital, Fruit St. 55, Boston, 02114, Massachusetts, USA

    Tracy Batchelor

  2. Dept. Neurology, Memorial Sloan-Kettering Cancer Center, York Ave. 1275, New York, 10021-6007, New York, USA

    Lisa M. DeAngelis

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Quant, E.C., Fisher, D.C., Wen, P.Y. (2012). Neurological Complications of Chemotherapy in Lymphoma and Leukemia Patients. In: Batchelor, T., DeAngelis, L. (eds) Lymphoma and Leukemia of the Nervous System. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7668-0_22

Download citation

Publish with us

Policies and ethics

Search

Navigation